Search results
Results from the WOW.Com Content Network
(Reuters) -Biogen's Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...
Leqembi's sales are projected to grow 13-fold to 56.5 billion yen ($361.28 million) in fiscal 2024 from the year ended in March, Eisai said in its annual results on Wednesday.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [ 2 ] [ 4 ] Lecanemab is an amyloid beta -directed antibody. [ 2 ] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [ 2 ]
GE Healthcare was poised to gain significant business after Medicare agreed to pay for Eisai and Biogen's Alzheimer's drug Leqembi after the FDA fully approved it earlier this year.
The following is a list of countries by passenger and cargo ship exports. Data is for 2023, in millions of United States dollars, as reported by The Observatory of Economic Complexity and the International Trade Centre. [1] [2] Currently the top twenty countries are listed. #
BAE Systems Maritime - Naval Ships [34] William Beardmore and Company (1900–1930) Fairfields (1834–1968) Robert Napier and Sons (1826–1900) [53] Greenock. Robert Steele & Company; Linthouse: Alexander Stephens & Sons (1870–1968) Port Glasgow. Ferguson Marine Engineering (1903–present) [54] William Hamilton and Company (1800s–1900s ...
Eisai said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list. Intravenous treatment of the drug, co ...